Huons’ overseas market expansion leads to record-high sales

South Korea's Huons Group is continuing its record-breaking performance while expanding its influence in the global market.

According to Huons Group on Tuesday, the consolidated financial statements of its holding company Huons Global for the first quarter of this year showed sales of 174 billion won ($136 million) and operating profit of 24.5 billion won ($19.1 million). These figures represent growth of 12% and 18.4% compared to the same period last year, respectively. Following a 16% growth in annual sales to 664.4 billion won ($518.9 million) last year compared to the previous year, the company continues to maintain double-digit growth momentum.

The company's business units have been enhancing their capabilities in their respective fields, and expanding exports to the North American market has had a significant positive impact.

By focusing on expanding in the North American and Japanese markets, the company has been increasing its global influence. With an increase in exports of injectable drugs to the North American region, last year's sales of anesthetics grew by 40% compared to the previous year. The export value of Lidocaine, a local anesthetic, to the US alone reached 12.3 billion won ($9.6 million).

Huons Group is also expanding its production lines. By the second half of 2025, the Jechon Plant 2 will complete the expansion of its injectable drug production line, tripling vial line production capacity from the current 26 million units to 79 million units and cartridge line production capacity from the current 132 million units to nearly 210 million units, an expansion of almost 60%.

The company is accelerating its global expansion in the Botulinum toxin and contract development and manufacturing organization (CDMO) businesses. Humedix, the company responsible for producing Elravie Premier, Revolline filler and Liztox Botulinum toxin, plans to expand its filler export countries to include China, Brazil and Central America.

Huons Biopharma has initiated the construction of a third biofactory for Hutox (the export name of Liztox) to expand its overseas presence. From next year, it will add an annual production capacity of 7.2 million vials, increasing its total production capacity to 13.68 million vials.

Huonland, a joint venture in China, is strengthening its efforts in the development of new eye drop products and CMO business.

Write to Ji-Hyun Lee at bluesky@hankyung.com